Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMTAS: Ramucirumab + TAS102 in mCRC
NCT03520946Phase 3Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jan 2019
- Primary completion
- Jul 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ramucirumab in colorectal cancer (CRC), sponsored by Institut für Klinische Krebsforschung. Started Jan 2019; status: completed.
02
Drugs
ramucirumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03520946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520946.